Zhibin Lin

Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study

Introduction SMARCA4‑deficient non‑small‑cell lung cancer (SMARCA4‑dNSCLC) is a rare, aggressive NSCLC subtype driven by SWI/SNF complex dysfunction with no standardized therapeutic strategies. Although chemoimmunotherapy represents standard first‑line therapy for driver‑negative advanced NSCLC, its real‑world efficacy...